Compare MDRR & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDRR | INTS |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 13.2M |
| IPO Year | N/A | 2021 |
| Metric | MDRR | INTS |
|---|---|---|
| Price | $11.41 | $5.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 1.2K | ★ 28.0K |
| Earning Date | 03-02-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $0.19 |
| 52 Week High | $14.52 | $8.06 |
| Indicator | MDRR | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 44.02 |
| Support Level | $11.00 | $5.04 |
| Resistance Level | $12.45 | $8.06 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 37.28 | 50.01 |
Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.